

## Mentoring and Outreach Scheme

One of the Academy's strategic goals is to develop the next generation of leading global medical researchers. Our Mentoring and Outreach Scheme offers a portfolio of activities that aim to promote academic medicine to medical students and clinicians in training, and to provide support and guidance to individuals as they embark on the academic pathway and progress to become established clinical academics.

Find out more about our work at [www.acmedsci.ac.uk](http://www.acmedsci.ac.uk) or visit [www.academicmedicine.ac.uk](http://www.academicmedicine.ac.uk) for information on careers in medical science.

Contact [mentoring@acmedsci.ac.uk](mailto:mentoring@acmedsci.ac.uk) to sign up for a regular e-bulletin.



## Clinical Academic Pathways – opportunities and future directions

### Programme

Wednesday 12 January 2011

41 Portland Place, London

The Academy is grateful to the National Institute for Health Research, NHS Education for Scotland and Queen's University Belfast for supporting the Mentoring and Outreach Scheme.



## Event agenda

|       |   |
|-------|---|
| 14.00 | Registration and refreshments   |
|       | <p><b>Plenary Session – <i>The Future of Health Research Funding</i></b><br/>(<i>John Newsom-Davis Council Chamber</i>)<br/>A series of presentations and a panel discussion introduced and chaired by: Professor Ronald Laskey CBE FRS FMedSci</p>   |
| 14.30 | <p><b>Professor Ronald Laskey CBE FRS FMedSci</b><br/>Vice President, The Academy of Medical Sciences<br/>Professor of Embryology, University of Cambridge</p>  |
| 14.40 | <p><b>Professor Dame Sally C. Davies FMedSci</b><br/>Director General of Research and Development, Chief Medical Officer (Interim) and Chief Scientific Adviser for the Department of Health and NHS</p>  |
| 15.00 | <p><b>Professor Sir John Savill FRSE FMedSci</b><br/>Chief Executive, Medical Research Council<br/>Vice-Principal and Head of the College of Medicine and Veterinary Medicine, University of Edinburgh</p>  |
| 15.20 | <p><b>Sir Mark Walport FMedSci</b><br/>Director, The Wellcome Trust</p>   |
| 15.40 | Panel discussion – audience Q&As  |
| 16.00 | Refreshments  |
| 16.20 | <p><b>Group discussions – <i>Grant Applications - What are funders looking for?</i></b></p> <p>Group A (<i>John Newsom-Davis Council Chamber</i>)<br/><b>Dr Lisa Cotterill</b>, Director, NIHR Trainees Coordinating Centre</p> <p>Group B (<i>John Newsom-Davis Reception Room</i>)<br/><b>Dr Peter Dukes</b>, Head of Research Careers Awards, Medical Research Council</p> <p>Group C (<i>Wolfson Conference Suite</i>)<br/><b>Dr John Williams</b>, Head of Clinical Activities, The Wellcome Trust</p> |
|       | <p><b>Plenary Session – <i>Interacting with Industry</i></b><br/>(<i>John Newsom-Davis Council Chamber</i>)</p>   |
| 17.10 | <p><b>Working in Industry</b><br/><b>Professor Nicholas La Thangue FRSE FMedSci</b><br/>Professor of Cancer Biology, University of Oxford</p>   |
| 17.30 | <p><b>Collaborating with Industry</b><br/><b>Sir Gregory Winter CBE FRS FMedSci</b><br/>Deputy Director, MRC Laboratory of Molecular Biology</p>  |
| 17.50 | Panel discussion – audience Q&As  |
| 18.10 | Drinks and networking with Academy Fellows  |
| 19.30 | Close   |

**Sir Gregory Winter CBE FRS FMedSci** is Deputy Director of the



Medical Research Council Laboratory of Molecular Biology (LMB) in Cambridge, and most of his scientific career has been based there. He is a graduate of Cambridge University (1973), specialising in chemistry and biochemistry; for his PhD (1976) and postdoctoral work (1977-1981) he specialized in protein and nucleic acid sequencing. From 1982 he pioneered the science of protein engineering, focusing first on enzymes (with Alan Fersht) and then antibodies. He invented

techniques to humanize rodent antibodies for use as therapeutics (1986), and later (also independently with Richard Lerner) to make fully human antibodies (1989) using combinatorial gene repertoires. His inventions are used in most of the antibody products on the market, including the humanized antibodies Campath-1H, Herceptin, Avastin, Synagis, and the first human antibody (Humira) to be approved by the US FDA. Sir Gregory is also an entrepreneur. He was a founder of Cambridge Antibody Technology (1989) and Domantis (2000); these companies pioneered the use of antibody repertoire technologies to make fully human antibody therapeutics, based on paired and unpaired variable domains respectively. Cambridge Antibody Technology floated on the London Stock Exchange in 1997 and was acquired by AstraZeneca in 2006, and Domantis was acquired by GSK in 2006 in a private sale. Together with Christian Heinis at the École Polytechnique Fédérale de Lausanne, he is now trying to develop very small protein mimics based on a covalently-bonded hydrophobic core, and has founded another company, Bicycle Therapeutics. Sir Gregory is a Fellow of Trinity College, Cambridge and a Fellow of the Royal Society, a Fellow of the Academy of Medical Sciences, an honorary Fellow of the Royal College of Physicians and of the Royal Society of Medicine. He was knighted in 2004 for services to science.

**Dr John Williams** trained initially as a neuroscientist at the National Institute for Medical Research, London.



*Wellcome Images*

Postdoctoral training followed at Stanford and Duke. In 1998 he changed direction and embarked on a career in science administration when he joined the Wellcome Trust. He has held a number of roles within the organisation. He is currently Head of Clinical Activities and Head of Neuroscience and Mental Health.

**Professor Nicholas La Thangue FRSE FMedSci** has over 20 years of



experience in biotechnology and healthcare. He founded Prolifix in 1995, a successful spin-out from the UK Medical Research Council, focussed on cancer drug discovery and was CSO until its merger with the Scandinavian oncology company TopoTarget. He acted as Chief Business Development Officer in TopoTarget, and was responsible for completing a number of significant deals with both large and mid size companies. Professor La Thangue has extensive scientific, commercial and financing experience derived from

the biotechnology sector. He is Professor of Cancer Biology at the University of Oxford, and was previously Cathcart Professor of Biochemistry at the University of Glasgow, and before that a scientist at the Medical Research Council. He studied for his PhD at University College London and carried out post-doctoral work at Imperial College London.

**Professor Ronald Laskey CBE FRS FMedSci** started his career at



Oxford, followed by post-doctoral posts on the scientific staff of Imperial Cancer Research Fund and the MRC Laboratory of Molecular Biology in Cambridge. In 1983 he moved to the Charles Darwin Chair of Animal Embryology in the University of Cambridge, first in the Department of Zoology, then as CRC Director of the Wellcome CRC Institute and more recently as Director of the MRC Cancer Cell Unit in the Hutchison/MRC Research Centre. Ron Laskey is a Fellow of the Royal Society, a Member of Academia Europaea,

Vice President of the Academy of Medical Sciences and a former President of the British Society for Cell Biology. His work has been recognised by several awards, including the Louis Jeantet Prize for Medicine.

**Professor Dame Sally C. Davies FMedSci** is the Director General (DG) of Research and Development and Chief Scientific Adviser for the Department of Health and NHS. As DG she developed NHS Research and Development into the National Institute for Health Research (NIHR). She also chairs the UK Clinical Research Collaboration (UKCRC) and is a member of the Board of the Office for Strategic Coordination of Health Research (OSCHR) and of the Medical Research Council. As a member of the WHO Global Advisory Committee on Health Research (ACHR) she chaired the Expert Advisory



Committee for the development of the WHO research strategy. Dame Sally has in addition, taken up the role of Chief Medical Officer until the substantive appointment is made.

**Professor Sir John Savill FRSE FMedSci** took up the position as Chief



Executive and Deputy Chair of the Medical Research Council (MRC) on 1 October 2010. Between 2008 and 2010 John worked part-time as the Chief Scientist for the Scottish Government Health Directorates. John started his research career with a degree in Physiological Sciences from Oxford University in 1978, followed by degrees in Medicine at the University of Sheffield in 1981. He received a PhD from the University of London in 1989. After junior hospital appointments in Sheffield, Nottingham and

London, he spent seven years in the Department of Medicine at Hammersmith Hospital with spells as an MRC Clinical Training Fellow and Wellcome Trust Senior Clinical Research Fellow. In 1993, he moved to the Chair of Medicine, at the University of Nottingham, then in 1998 became Professor of Medicine at the University of Edinburgh. In 2002, John was appointed as the first Vice-Principal and Head of the College of Medicine and Veterinary Medicine, University of Edinburgh.

**Sir Mark Walport FMedSci** is Director of the Wellcome Trust, which is



a global charitable foundation dedicated to achieving extraordinary improvements in health by supporting the brightest minds. Before joining the Trust he was Professor of Medicine and Head of the Division of Medicine at Imperial College London. He is a member of the Prime Minister's Council for Science and Technology, the India-UK CEO Forum, the advisory board of Infrastructure UK and a non-executive member of the Office for

Strategic Coordination of Health Research. He is a member of a number of international advisory bodies, including the Grand Challenges in Global Health Scientific Board and the Council of the Global HIV Vaccine Enterprise. He has undertaken independent reviews for the UK Government on the use and sharing of personal information in the public and private sectors: '*Data Sharing Review*' (2009) and secondary

education, '*Science and Mathematics: Secondary Education for the 21st Century*' (2010).

**Dr Lisa Cotterill** graduated BSc in Biochemistry from the University of



Liverpool in 1986 and PhD in Renal Preservation from the University of London in 1991. She spent several years as a Post-Doctoral Research Fellow at the Medical Research Council Clinical Sciences Centre in London where her research interests included T-cell interactions and immunotherapy in leukaemia. In January 2000, she moved into research management at the Medical Research Council maintaining their portfolio for health services and public health research including

research in primary care. Following two years as Assistant Director, she became Director of the NIHR Trainees Coordinating Centre (NIHR TCC) in May 2005. The NIHR TCC co-ordinates NIHR's research capacity development initiatives and is based at the Leeds Innovation Centre in Leeds.

**Dr Peter Dukes** is Head of Research Careers Awards in the Research



Programmes Group of the MRC. He is responsible for the development of funding policies for MRC's studentship and fellowship schemes and for supporting the work of the MRC's Training and Careers Group, which provides overall strategic oversight across research training and career development for the MRC. Peter is also policy lead for research data preservation and sharing, and is currently working with the population health sciences research community.